Imunon’s ovarian cancer trial continues after committee review

Markets Investing.com By Investing.com 23 Jun 2026 12:09 1 min read

Imunon’s ovarian cancer trial continues after committee review

Imunon’s ovarian cancer trial continues after committee review

Imunon’s ovarian cancer trial continues after committee review

Read the full story on Investing.com → Opens the original article on www.investing.com

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.